Fifth Circuit Restores In-Person Requirement for Mifepristone, Blocking Telehealth and Mail Access Nationwide

A federal appeals court in the United States sided with Louisiana in a fight over access to the abortion pill mifepristone, issuing a temporary nationwide injunction that reinstates an in-person requirement for prescribing and dispensing the drug.

“A report published on March 10 argues that the dangers of abortion pills increased for women after the U”

ACI Prensa

The Hill reported that a three-judge panel on the 5th U.S. Circuit Court of Appeals “sided with Louisiana” and blocked doctors from prescribing mifepristone “through telehealth and dispensed through the mail,” restoring a 2021 nationwide requirement that mifepristone “must be prescribed and dispensed in person.”

ACI Prensa

NBC News described the same Friday ruling as “a victory for opponents of abortion rights,” saying it limits access by blocking people’s ability to obtain mifepristone through telehealth and by mail.

The decision also set up a likely appeal to the Supreme Court, with The Hill writing that the ruling “sets up a likely appeal to the Supreme Court.”

In the Fifth Circuit’s reasoning, Politico quoted the judges saying “The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law.”

Politico further said the decision restores the FDA’s prior policy mandating that patients only obtain the drug “in person from a physician,” and it applied to both states that ban abortion and those that allow it.

The ruling’s immediate effect was described as curtailing access nationwide to a drug used in “more than two-thirds of abortions,” according to Politico’s framing of the impact.

The legal battle described across the reports traces back to changes in FDA rules that expanded how mifepristone could be accessed, and to Louisiana’s argument that those changes undermined its abortion ban.

The Hill said the FDA “permanently lifted the in-person requirement in 2023,” which it described as leading to “a surge in pills prescribed over the internet” after the Dobbs ruling overturned the constitutional right to an abortion.

ADF Media

NBC News similarly said that during the Covid pandemic the FDA “temporarily eliminated a requirement for mifepristone to be dispensed only in clinics, medical offices and hospitals,” and that the change was then made permanent in 2023.

In the Fifth Circuit’s view as reported by The Hill, Louisiana argued that the FDA rules made it “easier for abortion pills to be mailed into states where abortion is banned.”

The appeals court’s decision Friday was also framed as reversing an earlier lower-court pause, with The Hill writing that it “overrides a lower court’s ruling earlier this month that had paused the lawsuit while the Trump administration’s FDA conducts a review on the safety of mifepristone.”

CNN added that the district judge in Lafayette, Louisiana, had refused to block mail-order distribution “at least for now,” while warning that the pause would not be indefinite and that he could side with Louisiana later.

CNN said the FDA and the U.S. Department of Health and Human Services announced they would review the safety and efficacy of mifepristone, and it reported that Judge David Joseph asked the agency to update him “within six months.”

The ruling drew sharply contrasting reactions from abortion-rights advocates, anti-abortion groups, and the pharmaceutical industry.

“Opponents of the abortion 'engendro' in the United States are increasingly frustrated by what they see as the administration's missteps under President Donald Trump to curb the flow of prescription abortion pills delivered via telehealth, which they say undermine state bans on the engendro”

Bitacora.uy

The Hill quoted Brittany Fonteno, CEO of The National Abortion Federation, saying, “Make no mistake: this ruling is not grounded in science or patient safety,” and adding that it “is a politically-driven decision that overrides medical expertise and years of research, and threatens to upend how abortion care is delivered nationwide.”

The Hill also quoted Sen. Patty Murray (D-Wash.) saying, “Mifepristone is safe and effective—millions of women have used this medication since the FDA approved it over 25 years ago,” and she argued that “The only reason mifepristone is regulated as heavily as it already is, is because of anti-abortion politics, not because of science.”

NBC News quoted Julia Kaye of the ACLU’s Reproductive Freedom Project: “Anti-abortion politicians have just made it much harder for people everywhere in the country to get a medication that abortion and miscarriage patients have been safely using for more than 25 years.”

On the other side, Politico included a quote from Gavin Oxley, a spokesperson for Americans United for Life, saying, “The era of mail-order abortion is near its end.”

Politico also quoted GenBioPro CEO Evan Masingill warning that the court ignored science, stating, “We are alarmed by this court’s decision to ignore the FDA’s rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents.”

NBC News added that Masingill said, “We are reviewing the court’s order in detail,” and it quoted Alexis McGill Johnson, CEO of Planned Parenthood Action Fund, saying the organization’s health centers “remain committed to providing abortion care where legal.”

While the core outcome—reinstating an in-person requirement and blocking telehealth and mail-order access—was consistent, the outlets diverged in emphasis and language about what the decision means.

The Hill framed the ruling as a nationwide restriction and a “likely appeal to the Supreme Court,” while describing it as a “victory for opponents of abortion rights” in NBC News’s account.

CNN en Español

NBC News emphasized access barriers, saying the ruling “limits access by blocking people's ability to obtain mifepristone — one of the two pills used in medication abortions — through telehealth and by mail,” and it highlighted telehealth as key to maintaining access after Roe was overturned.

Politico, by contrast, emphasized the legal reasoning and the scope, describing the decision as “arguably the biggest rollback in access to abortion since the Supreme Court’s 2022 ruling overturning Roe v. Wade,” and it quoted the judges’ view that the regulation undermined Louisiana’s laws and caused “irreparable harm.”

CNN en Español focused on the earlier district court stage, describing a “setback for Louisiana's bid” when Judge David Joseph refused to block mailing “at least for now,” and it stressed that the FDA and HHS would review safety and efficacy.

The Independent en Español and Bitacora.uy both centered on anti-abortion opponents’ frustration, with Kristi Hamrick saying, “Delay tactics are more than frustrating,” and with Bitacora.uy using the phrase “Procedural tactics are more than frustrating.”

France 24 added a different framing by describing an appeals court decision that would have “no practical effect” until the Supreme Court, and it said the decision would mean “a return to a seven-week pregnancy limit instead of ten, a ban on mailing the abortion pill, and the reinstatement of the requirement that prescription be provided exclusively by a physician.”

The next steps described in the reporting center on appeals to the Supreme Court and on how the FDA’s review process will interact with court orders.

“A federal judge refused on Tuesday to block mail-order distribution of prescriptions for the abortion pill mifepristone across the United States, at least for now”

CNN en Español

The Hill said the Friday ruling “sets up a likely appeal to the Supreme Court,” and it also described that it “overrides a lower court’s ruling earlier this month” that had paused the lawsuit while the Trump administration’s FDA conducted a safety review.

Courrier international

NBC News similarly described the ruling as a victory for opponents and noted that Louisiana had challenged the FDA regulation in federal court, with the FDA requesting in January that the lawsuit be paused until the Trump administration finished its own safety review.

CNN en Español added that Judge David Joseph asked the FDA to update him “within six months” and warned that if the agency did not complete its review and make necessary modifications “within a reasonable time,” the court’s analysis would change.

Politico described the decision as teeing up a “SCOTUS showdown,” and it said the court rejected arguments that the state lacked standing and that the court should pause while the FDA reviewed the drug.

The reporting also indicates that the case is part of a broader set of legal fights, including state-level actions against out-of-state doctors accused of mailing abortion pills.

CNN en Español said Murrill was pursuing criminal cases against two doctors, “one in California and the other in New York,” accused of sending pills to patients in Louisiana, and it noted that those states had not been willing to extradite the doctors.